Kohima News Paper

The market dynamics of Primary Hyperoxaluria are expected to change in the upcoming years as diagnostic methodologies improve and new therapies are introduced

 Breaking News
  • No posts were found

The market dynamics of Primary Hyperoxaluria are expected to change in the upcoming years as diagnostic methodologies improve and new therapies are introduced

June 18
20:05 2021
The market dynamics of Primary Hyperoxaluria are expected to change in the upcoming years as diagnostic methodologies improve and new therapies are introduced

Primary Hyperoxaluria Market
The rise in the number of patients with Primary Hyperoxaluria is a primary driver of market expansion in 7MM.

DelveInsight’s Primary Hyperoxaluria market report gives a comprehensive understanding of Primary Hyperoxaluria epidemiology, market trends, and historical and predicted epidemiology in the 7MM. The report also discusses current Primary Hyperoxaluria treatment practices/algorithms, market drivers, market barriers, and unmet medical needs in order to curate the best opportunities and assess the market’s underlying potential.

Some of the Key Highlights from the Primary Hyperoxaluria Market Report

  • According to the National Institutes of Health, 1 in 58,000 people worldwide suffer from Primary Hyperoxaluria. Type 1 is the most common, accounting for roughly 80% of all cases. Types 2 and 3 account for about 10% of all cases.

  • According to Orphanet, the prevalence of Primary Hyperoxaluria (PH) varies between 1-3/1 000 000, and the annual incidence is predicted to be between 1-2/10 000 000, with no gender differences.

  • A few of the potential emerging therapy for Primary Hyperoxaluria include Stiripentol (Biocodex), Oxabact OC5 – Oxalobacter formigenes HC-1 (OxThera), Lumasiran (Alnylam Pharmaceuticals), DCR-PHXC (Dicerna Pharmaceuticals), and others.

  • Biocodex, OxThera, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals are among the key players, which are involved in the development of emerging drugs in the Primary Hyperoxaluria market.

To know more request sample @ Primary Hyperoxaluria Market Outlook

The Primary Hyperoxaluria market report covers current treatment practises, emerging drugs, individual therapies’ Primary Hyperoxaluria market share, and current and forecasted Primary Hyperoxaluria market Size from 2018 to 2030, segmented by seven major markets.

Primary Hyperoxaluria: Disease Overview

Primary Hyperoxaluria (PH) is a rare condition that causes recurring kidney and bladder stones. End stage renal disease (ESRD) is a life-threatening condition that prevents the kidneys from effectively filtering fluids and waste products from the body. The overproduction of a chemical called oxalate causes Primary Hyperoxaluria. Oxalate is excreted as a waste product in urine after being filtered by the kidneys, resulting in abnormally high levels of this substance in urine (hyperoxaluria).

Primary Hyperoxaluria Epidemiology Segmentation

  • Primary Hyperoxaluria Prevalent Cases

  • Primary Hyperoxaluria Type-Specific Prevalent Cases

  • Primary Hyperoxaluria Age-Specific Prevalent Cases

  • Primary Hyperoxaluria Diagnosed and Treatable Cases

Primary Hyperoxaluria Treatment Landscape

There are currently no approved medicines for the treatment of Primary Hyperoxaluria, and the current therapeutic market for Primary Hyperoxaluria is based on therapies such as enzyme reactivation therapy, gene therapies, and RNA-interference-based substrate reduction therapy.Chemical chaperones, supplement intake, hepatocyte transplantation, and dialysis are some of the other therapy possibilities, while generic nephrolithiasis medicines benefit all people with PH.

Primary Hyperoxaluria Market

The rise in the number of prevalent cases of Primary Hyperoxaluria patients in 7MM is a major driver of market growth. The anticipated launch of pipeline therapies such as stiripentol, Lumasiran, DCR-PHXC, and others will drive market growth during the forecast period, i.e., 2021–2030.

Reach out for more @ Primary Hyperoxaluria Market Analysis

Primary Hyperoxaluria Pipeline Therapies and Key Companies

  • Stiripentol: Biocodex

  • Oxabact OC5 – Oxalobacter formigenes HC-1: OxThera

  • Lumasiran: Alnylam Pharmaceuticals

  • DCR-PHXC: Dicerna Pharmaceuticals

Table of Contents 


Report Introduction


Primary Hyperoxaluria Market Share at a glance


Disease Background and Overview


Primary Hyperoxaluria Epidemiology and Patient Population


Country Wise: Epidemiology of Primary Hyperoxaluria


Primary Hyperoxaluria Current Treatment & Medical Practices


Primary Hyperoxaluria Emerging Therapeutics


Primary Hyperoxaluria Market Size


Region-Wise Market size of Primary Hyperoxaluria (2018-2030)


Primary Hyperoxaluria Market Drivers


Primary Hyperoxaluria Market Barriers


Analyst Views


Future Perspectives




Report Methodology


DelveInsight Capabilities




About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Primary Biliary Cholangitis Market

Get comprehensive historical and forecast analysis of Primary Biliary Cholangitis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKlineamong others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/